Rappta Therapeutics Company Profile

Background

Rappta Therapeutics is a late preclinical-stage biopharmaceutical company dedicated to developing first-in-class anti-cancer drugs that reactivate protein phosphatase 2A (PP2A), a critical tumor suppressor enzyme. By leveraging proprietary tools and a deep understanding of PP2A, Rappta aims to introduce a new class of anti-cancer therapies targeting a broad spectrum of human cancers.

Key Strategic Focus

Rappta's strategic focus centers on the therapeutic reactivation of PP2A to inhibit tumor growth. Utilizing proprietary high-resolution structural data, the company has developed a series of molecular glues designed to restore PP2A activity. This approach targets oncogenic drivers in specific cancer subsets, such as uterine cancers with PP2A mutations, addressing significant unmet medical needs.

Financials and Funding

In October 2020, Rappta secured a €9 million Series A financing co-led by Novartis Venture Fund and Novo Holdings, with participation from Advent Life Sciences and a family office. Additionally, the company received funding from Business Finland. These funds are allocated to advancing lead compounds to the clinical candidate stage.

Pipeline Development

Rappta's lead asset, RPT04402, is a first-in-class molecular glue targeting specific PP2A complexes. Preclinical models have demonstrated that RPT04402 induces rapid, deep, and durable tumor regressions as a monotherapy in PP2A-mutant uterine cancers. In January 2025, Rappta entered into an exclusive global license agreement with SpringWorks Therapeutics for the development and commercialization of RPT04402. SpringWorks plans to file an Investigational New Drug (IND) application by the end of 2025.

Technological Platform and Innovation

Rappta's innovation lies in its proprietary approach to reactivating PP2A, a previously undruggable target. The company's platform utilizes high-resolution structural data to design molecular glues that restore PP2A's tumor-suppressive function. This technology has the potential to create a new class of anti-cancer drugs applicable to a wide range of human cancers.

Leadership Team

Sunjeet Sawhney, Chief Executive Officer: Appointed in September 2021, Sunjeet brings over 20 years of industry experience, including his role as Global Head of the Oncology Franchise at Ipsen.

Mikko Mannerkoski, Chief Financial Officer and Co-Founder: Transitioned from CEO to CFO in 2021, Mikko co-founded Rappta and has been instrumental in securing funding and strategic partnerships.

Goutham Narla, Chief Scientific Officer and Co-Founder: A Professor of Internal Medicine and Human Genetics at the University of Michigan, Goutham leads Rappta's scientific endeavors with his extensive expertise in PP2A biology.

Leadership Changes

In September 2021, Rappta appointed Sunjeet Sawhney as CEO, with Co-Founder Mikko Mannerkoski transitioning to CFO. This strategic leadership change aims to guide the company through its next growth phases.

Competitor Profile

Market Insights and Dynamics

The oncology therapeutics market is highly competitive, with numerous companies developing innovative treatments targeting various cancer pathways. The focus on previously undruggable targets like PP2A represents a significant advancement in cancer therapy.

Competitor Analysis

While specific competitors targeting PP2A are limited, companies such as Agenus, ChemoCentryx, and AnaptysBio are notable in the broader oncology therapeutics space. These companies focus on immuno-oncology and small molecule therapies, contributing to the dynamic and competitive landscape.

Strategic Collaborations and Partnerships

In January 2025, Rappta entered into an exclusive global license agreement with SpringWorks Therapeutics for RPT04402. Under this agreement, SpringWorks is responsible for the global development and commercialization of RPT04402, with Rappta receiving a $13 million upfront payment and potential milestone payments.

Operational Insights

Rappta's proprietary PP2A-reactivating technology positions the company uniquely in the oncology market. By targeting a previously undruggable enzyme, Rappta differentiates itself from competitors and addresses unmet medical needs in cancer treatment.

Strategic Opportunities and Future Directions

Rappta aims to advance its PP2A-reactivating compounds through clinical development, leveraging strategic partnerships to accelerate commercialization. The company's innovative approach offers potential applications across various cancer types, positioning it for significant impact in oncology therapeutics.